Skip to Content
Merck
CN

A9666

Azaserine-Hypoxanthine 50x

Hybri-Max™, γ-irradiated, lyophilized powder, BioXtra, suitable for hybridoma

Synonym(s):

O-Diazoacetyl-L-serine-hypoxanthine

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

NACRES:
NA.75
UNSPSC Code:
12352207

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Azaserine-Hypoxanthine 50x, Hybri-Max™, γ-irradiated, lyophilized powder, BioXtra, suitable for hybridoma

biological source

synthetic (organic)

grade

Hybri-Max™

sterility

γ-irradiated

product line

BioXtra

form

lyophilized powder

technique(s)

cell culture | hybridoma: suitable

impurities

endotoxin, tested

shipped in

dry ice

storage temp.

−20°C

Quality Level

200

Related Categories

Application

Azaserine-Hypoxanthine 50x has been used in hybridoma cell culture.
Qualified for use in hybridoma cell culture applications as a selection agent.

General description

Azaserine-Hypoxanthine is used to stimulate cell proliferation in cell culture.

Preparation Note

Reconstitute contents of vial with 10 mL sterile cell culture medium. Stock solution is sufficient to prepare 500 mL medium. Final working concentration: 5.7 μM azaserine, 100 μM hypoxanthine.

Legal Information

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

hcodes

H302,H351

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000445023
0000445023
0000418673
0000418673
0000399437

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Handbook of Mutagenicity Test Procedures, 350-350 (2012)
Receptor editing: an approach by autoreactive B cells to escape tolerance.
Gay D,et al.
The Journal of Experimental Medicine, 177(4), 999-1008 (1993)
Handbook of Mutagenicity Test Procedures, 350-350 (2012)
Michael X Henderson et al.
Neurobiology of disease, 136, 104712-104712 (2019-12-15)
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are progressive neurodegenerative diseases for which there is no disease-modifying treatment. PD and DLB are characterized by aggregation of the synaptic protein α-synuclein, and there is compelling evidence to suggest that

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service